Anal cancer: emerging standards in a rare disease
C Eng, KK Ciombor, M Cho, JA Dorth… - Journal of Clinical …, 2022 - ascopubs.org
The social stigma surrounding an anal cancer diagnosis has traditionally prevented open
discussions about this disease. However, as recent treatment options and an increasing rate …
discussions about this disease. However, as recent treatment options and an increasing rate …
[HTML][HTML] Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: A nationwide cohort study
A de Haar-Holleman, LMC van Hoogstraten… - Radiotherapy and …, 2023 - Elsevier
Background and purpose Oral capecitabine and intravenous 5-fluorouracil (5-FU) are both
used as a radiosensitizer in chemoradiotherapy (CRT). A capecitabine-based regimen is …
used as a radiosensitizer in chemoradiotherapy (CRT). A capecitabine-based regimen is …
[HTML][HTML] Preliminary results on anal cancer by applying intensity modulated radiotherapy and synchronous capecitabine chemotherapy simultaneously
WD Xu, HY Jiang, JM Gao, JF Du, G Chen… - Translational Cancer …, 2020 - ncbi.nlm.nih.gov
Background Anal cancer is a rare clinical disease with the incidence rate of 1–2/10 million.
The present study aims to assess the feasibility, safety and short-term outcome of the …
The present study aims to assess the feasibility, safety and short-term outcome of the …
Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer
L Mineur, L Vazquez, M Belkacemi, C Toullec… - Current …, 2023 - mdpi.com
Since EXTRA, a non-randomized phase II trial with 31 patients, explored the use of
capecitabine, mitomycin and radiation therapy (RT) in the treatment of localized squamous …
capecitabine, mitomycin and radiation therapy (RT) in the treatment of localized squamous …